Results 261 to 270 of about 293,272 (302)
Driving CAR T-cells forward [PDF]
Nature Reviews Clinical Oncology, 2016 The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the treatment of patients with cancer showed modest results, but the impressive outcomes of several trials of CD19-targeted CAR T cells in the treatment of patients with B ...
Sarwish Rafiq, Renier J Brentjens
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Onkologische Pflege, 2020
Die CAR-T-Zell-Therapie ist eine Immuntherapie, bei der körpereigene T-Zellen entnommen, gentechnisch verändert und dem Körper anschließend wieder zugeführt werden, um dann die Tumoroberfläche zu erkennen und die Tumorzelle zu zerstören. Häufig auftretende Nebenwirkungen sind Zytokinsturm und Neurotoxizität, die eine engmaschige Überwachung der ...
Barbara Huber, Chrissoula Kiote-Schmidt
openaire +1 more source
Die CAR-T-Zell-Therapie ist eine Immuntherapie, bei der körpereigene T-Zellen entnommen, gentechnisch verändert und dem Körper anschließend wieder zugeführt werden, um dann die Tumoroberfläche zu erkennen und die Tumorzelle zu zerstören. Häufig auftretende Nebenwirkungen sind Zytokinsturm und Neurotoxizität, die eine engmaschige Überwachung der ...
Barbara Huber, Chrissoula Kiote-Schmidt
openaire +1 more source
2022
Adaptive immunotherapy has been growing as a therapeutic alternative for cancer and other diseases treatment; chimeric antigen receptor (CAR) T cells comprise a type of adaptive immunotherapy, with recombinant receptor constructs expressed in T cells to target cells expressing specific antigens, is a potential new treatment for blood cancers and solid ...
openaire +2 more sources
Adaptive immunotherapy has been growing as a therapeutic alternative for cancer and other diseases treatment; chimeric antigen receptor (CAR) T cells comprise a type of adaptive immunotherapy, with recombinant receptor constructs expressed in T cells to target cells expressing specific antigens, is a potential new treatment for blood cancers and solid ...
openaire +2 more sources
C&EN Global Enterprise, 2018
Last August, in a milestone decades in the making, Kymriah became the first cell therapy to be approved by the U.S. Food & Drug Administration. Marketed by the Swiss giant Novartis, Kymriah is made by genetically engineering an individual’s own immune cells to attack a form of leukemia.
openaire +1 more source
Last August, in a milestone decades in the making, Kymriah became the first cell therapy to be approved by the U.S. Food & Drug Administration. Marketed by the Swiss giant Novartis, Kymriah is made by genetically engineering an individual’s own immune cells to attack a form of leukemia.
openaire +1 more source
Overcoming CAR T cell exhaustion
Nature Reviews Immunology, 2019Overexpression of JUN by CAR T cells renders them resistant to exhaustion and improves tumour control in mouse models, including of solid tumours and of tumours with low levels of antigen expression.
openaire +2 more sources
Best Practice & Research Clinical Haematology, 2018
The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these, and other CAR-T cells, in-house. This article reviews the issues that must be addressed in order to achieve this goal.
openaire +2 more sources
The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these, and other CAR-T cells, in-house. This article reviews the issues that must be addressed in order to achieve this goal.
openaire +2 more sources
MedScien
CAR-T (Chimeric antigen receptor T) cell therapy is an immunotherapy especially effective in treating hematological tumors.
openaire +1 more source
CAR-T (Chimeric antigen receptor T) cell therapy is an immunotherapy especially effective in treating hematological tumors.
openaire +1 more source
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
New England Journal of MedicineIndolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells.
Metin, Ozdemirli +9 more
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2023
Caron A. Jacobson, Parth S. Shah
openaire +1 more source
Caron A. Jacobson, Parth S. Shah
openaire +1 more source